您当前的位置:
技术服务
发布日期:2024/7/17 15:27:00

Title:In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts

标题: 泊沙康唑、氟康唑、伊曲康唑、伏立康唑和两性霉素B对大量临床重要霉菌酵母的体外活性

Authors: Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas P

作者: Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas P

Journal: Antimicrobial Agents and Chemotherapy

期刊: 抗微生物剂与化疗学

Published: June 2006; Volume 50, Issue 6, Pages 2009-2015

出版时间: 2006年6月;第50卷,第6期,2009-2015页

DOI: 10.1128/AAC.50.6.2009-2015.2006

Abstract

The study assesses the antifungal efficacy of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a comprehensive collection of clinically significant molds and yeasts. Results indicate that posaconazole shows superior activity compared to other azoles, especially against several mold species.

摘要

该研究评估了曲安奈德、氟康唑、伊曲康唑、伏立康唑和两性霉素B对大量临床重要霉菌和酵母菌的抗真菌效果。结果表明,曲安奈德对多种霉菌的活性优于其他唑类药物。

Introduction

This paper aims to compare the in vitro activity of five antifungal agents against a broad spectrum of fungi, given the rising concern over fungal infections and the necessity for effective treatment options.

引言

本文旨在比较五种抗真菌剂对多种真菌的体外活性,鉴于真菌感染的日益严重以及对有效治疗方案的需求。

Methods

  • Isolates: The study included 1,025 clinical isolates from different geographical locations.
  • Testing: The minimum inhibitory concentrations (MICs) were determined using the NCCLS (National Committee for Clinical Laboratory Standards) broth microdilution method.

方法

  • 分离株: 研究包括来自不同地理位置的1025个临床分离株。
  • 测试: 使用NCCLS(国家临床实验室标准委员会)肉汤微量稀释法测定最小抑菌浓度(MIC)。

Results

  • Yeasts: Posaconazole demonstrated the most potent activity against Candida spp. and Cryptococcus neoformans.
  • Molds: It also showed superior activity against Aspergillus spp., Fusarium spp., and other rare molds.
  • Comparative Analysis: Amphotericin B remained effective, but posaconazole was generally more potent than other azoles.

 

结果

  • 酵母菌: 曲安奈德对念珠菌属和新生隐球菌表现出最强的活性。
  • 霉菌: 对曲霉菌属、镰刀菌属及其他罕见霉菌也表现出优异的活性。
  • 比较分析: 两性霉素B仍然有效,但曲安奈德通常比其他唑类药物更有效。

 

 

Discussion

The study highlights posaconazole as a promising antifungal agent, particularly for treating infections caused by molds and azole-resistant yeasts. The results support its use in clinical settings where broad-spectrum antifungal activity is required.

讨论

该研究强调了曲安奈德作为一种有前途的抗真菌剂,特别适用于治疗霉菌和唑类抗性酵母菌引起的感染。结果支持其在需要广谱抗真菌活性的临床环境中的使用。

Conclusion

Posaconazole exhibits strong in vitro activity against a wide array of clinically important fungi, suggesting its potential as a leading antifungal therapy.

结论

曲安奈德对多种临床重要真菌表现出强大的体外活性,表明其作为主要抗真菌治疗的潜力。

Compounds and CAS Numbers

 

1. Posaconazole (曲安奈德): CAS 171228-49-2

2. Fluconazole (氟康唑): CAS 86386-73-4

3. Itraconazole (伊曲康唑): CAS 84625-61-6

4. Voriconazole (伏立康唑): CAS 137234-62-9

5. Amphotericin B (两性霉素B): CAS 1397-89-3

 

相关产品

Amphotericin B. 1397-89-3
|500mg
伏立康唑. 137234-62-9
|250mg
Fluconazole. 86386-73-4
|100mg
(±)14(15)-EET-d11.
询价
|10mg
泊沙康唑. 171228-49-2
|10mg
伏立康唑. 137234-62-9
|20mg
伊曲康唑. 84625-61-6
|20mg
上一篇:盐酸胺碘酮和泊沙康唑对克鲁兹锥虫生长及超微结构的影响 下一篇:营养补充剂对健康志愿者口服后泊沙康唑药代动力学的影响